← Leaderboards
Keri Hammel
The Emmes Company, Llc
$53,700,408
Attributed
$53,700,408
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $7.3M · FY2014–21$10M$7.5M$5M$2.5M$0
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$53,700,408 · 2
By mechanism
N01$53,700,408 · 2
Top collaborators
No co-investigators on record.
Most similar at The Emmes Company, Llc
Same institution · by research overlap
- Supriya Menezes$25,277,032
- Darby Thompson$10,610,431
- Keri, Hammel$11,064,901
Others in their field
Top investigators on “Diagnosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$590,717,255
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$337,858,596
- Richard K. Wilson · Washington University$297,645,172
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Carol Nesel · Westat$188,148,170
Research focus
DiagnosisDna RepositoryData ManagementDesignDatabasesDiabetic RetinopathyClinical TrialsData AnalysesClinical ResearchDark AdaptationColobomaCollectionContractsContractorBiobankAge RelatedArea AnalysesAge Related Macular DegenerationCase-Control StudiesCell LineAcquired Immunodeficiency SyndromeCentral Retinal Vein OcclusionActive MethodEarly Treatment
Grant awards (8)
IGF::OT::IGFEMMES NEIS-V$7,315,897
N01 · FY2021 · OD · contact PI
IGF::OT::IGFEMMES NEIS-V$7,212,964
N01 · FY2020 · OD · contact PI
IGF::OT::IGFEMMES NEIS-V$7,217,805
N01 · FY2019 · OD · contact PI
IGF::OT::IGFEMMES NEIS-V$7,243,461
N01 · FY2018 · OD · contact PI
IGF::OT::IGFEMMES NEIS-V$6,718,044
N01 · FY2017 · OD · contact PI
STATISITICAL DESIGN, MONITORING & COORD. OF VISION CLINICAL TRIALS & EPIDEMIOLOGY$6,040,432
N01 · FY2016 · EY · contact PI
STATISITICAL DESIGN, MONITORING & COORD. OF VISION CLINICAL TRIALS & EPIDEMIOLOGY$5,892,755
N01 · FY2015 · EY · contact PI
STATISITICAL DESIGN, MONITORING & COORD. OF VISION CLINICAL TRIALS & EPIDEMIOLOGY$6,059,050
N01 · FY2014 · EY · contact PI